Ascendis Pharma A/S

ASND

US04351P1012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
138.6 ^USD	-1.58%		+0.90%	+10.02%

09/07	European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	MT
05/07	Ascendis Pharma, Pendopharm Sign Distribution Agreement for TransCon Parathyroid Hormone in Canada	MT

Ascendis Pharma A/S(NasdaqGS:ASND) added to NASDAQ Composite Index

January 29, 2015 at 10:30 am IST

Ascendis Pharma A/S has been added to NASDAQ Composite Index.

Latest news about Ascendis Pharma A/S

European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	09/07	MT
Ascendis Pharma, Pendopharm Sign Distribution Agreement for TransCon Parathyroid Hormone in Canada	05/07	MT
Pendopharm Signs Exclusive Distribution Agreement with Ascendis Pharma A/S for TransCon PTH in Canada	04/07	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	03/07	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	02/07	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	01/07	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	26/06	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading	25/06	MT
TD Cowen Upgrades Ascendis Pharma to Buy Rating With $175 Price Target	25/06	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher	21/06	MT
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	17/06	MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading	12/06	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading	11/06	MT
Transcript : Ascendis Pharma A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM	11/06
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	05/06	MT
Ascendis Pharma Reports 45% Clinical Response in TransCon IL-2 Phase 1/2 Trial	04/06	MT
Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024	04/06	CI
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower	31/05	MT
Stifel Initiates Ascendis Pharma at Buy Rating With $200 Price Target	31/05	MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	22/05	MT
Morgan Stanley Adjusts Ascendis Pharma Price Target to $140 From $116, Maintains Equal Weight Rating	16/05	MT
US Equity Markets Close Higher Tuesday as Producer Prices Rise	15/05	MT
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	15/05	MT
Sector Update: Health Care	15/05	MT
Ascendis Pharma Says US FDA Extends Review Period on Hypoparathyroidism Treatment; Shares Drop	15/05	MT

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Sector

Biotechnology & Medical Research

Calendar

29/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ascendis Pharma A/S

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

126.7 EUR

Average target price

167.1 EUR

Spread / Average Target

+31.89%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ASCENDIS PHARMA A/S	+10.02%	794.7Cr
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	13TCr
REGENERON PHARMACEUTICALS, INC.	+23.61%	12TCr
ARGENX SE	+22.56%	2.75TCr
BIONTECH SE	-18.07%	2.09TCr
GENMAB A/S	-14.06%	1.7TCr
BEIGENE, LTD.	-14.81%	1.63TCr
NEUROCRINE BIOSCIENCES, INC.	+9.78%	1.46TCr
WUXI APPTEC CO., LTD.	-46.10%	1.51TCr
SAREPTA THERAPEUTICS, INC.	+52.34%	1.39TCr

Bio Therapeutic Drugs